Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Conterno is new Lilly U.S. president

Executive Summary

Lilly's U.S. president Deirdre Connelly resigned and will be succeeded by Enrique Conterno, currently senior VP for U.S. health care professional markets, the firm announces Jan. 30. Conterno perhaps beefed up his resume for the job after being appointed more responsibilities last year in overseeing efforts toward health professionals and neuroscience, diabetes and osteoporosis therapeutics when the company restructured to streamline R&D (1"The Pink Sheet," June 2, 2008, p. 25). The leadership shift is effective immediately

You may also be interested in...



Lilly’s former U.S. president joins GSK

Deirdre Connelly joins GlaxoSmithKline as President North American Pharmaceuticals, effective Feb. 9. CEO Andrew Witty said Connelly's track record aligns with the firm's plan to increase payer and physician focus for sales reps in the U.S. Connelly resigned from her position as head of Lilly's U.S. operations Jan. 30 (1"The Pink Sheet," Feb. 2, 2009, In Brief)

Altus Names Gemayel CEO; Milligan Becomes Gilead President

Presidents & CEOs

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel